Antimitotic drugs in cancer chemotherapy: Promises and pitfalls

Biochemical Pharmacology

Volumn 86, Issue 6, 2013, Pages 703-710

  Marzo, Isabel ^a   Naval, Javier ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Cancer; Chemotherapy; Mitosis

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; AURORA KINASE INHIBITOR; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; DOXORUBICIN; FLAVOPIRIDOL; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; JNJ 7706621; LENALIDOMIDE; MITOXANTRONE; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; OXALIPLATIN; P 276 00; PURVALANOL B; RITUXIMAB; SANGIVAMYCIN LIKE MOLECULE 6; TG 02; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CHROMOSOMAL INSTABILITY; DRUG POTENTIATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; IN VITRO STUDY; MITOSIS; MITOSIS INHIBITION; MYELOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84885185563     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.07.010     Document Type: Note

References (89)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
2. Yu Q, La Rose J, Zhang H, Takemura H, Kohn KW, Pommier Y. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Research 2002; 62: 5743-8. (Pubitemid 35204730)
3. Dudgeon C, Wang P, Sun X, Peng R, Sun Q, Yu J, et al. PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01. Molecular Cancer Therapeutics 2010; 9: 2893-902.
4. Vogel C, Hager C, Bastians H. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Research 2007; 67: 339-45. (Pubitemid 46142793)
5. Komlodi-Pasztor E, Sackett DL, Fojo AT. Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clinical Cancer Research 2012; 18: 51-63.
6. Rathos MJ, Khanwalkar H, Joshi K, Manohar SM, Joshi KS. Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P 276-00 in human non-small cell lung cancer cells. BMC Cancer 2013; 13: 29.
7. Alvarez-Fernandez S, Ortiz-Ruiz MJ, Parrott T, Zaknoen S, Ocio EM, San Miguel J, et al. Potent antimyeloma activity of a novel ERK5/CDK inhibitor. Clinical Cancer Research 2013; 19: 2677-87.
8. Dolloff NG, Allen JE, Dicker DT, Aqui N, Vogl D, Malysz J, et al. Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9. Molecular Cancer Therapeutics 2012; 11: 2321-30.
9. Ringer L, Sirajuddin P, Heckler M, Ghosh A, Suprynowicz F, Yenugonda VM, et al. VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells. Cancer Biology and Therapy 2011; 12: 818-26.
10. van der Waal MS, HengeveldRC, van der Horst A, Lens SM. Cell division control by the chromosomal passenger complex. Experimental Cell Research 2012; 318: 1407-20.
11. Zhou N, Singh K, Mir MC, Parker Y, Lindner D, Dreicer R, et al. The investigational aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clinical Cancer Research 2013; 19: 1717-28.
12. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nature Reviews Drug Discovery 2009; 8: 547-66.
13. Deeraksa A, Pan J, Sha Y, Liu XD, Eissa NT, Lin SH, et al. Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis. Oncogene 2013; 32: 2973-83.
14. Simizu S, Osada H. Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines. Nature Cell Biology 2000; 2: 852-4.
15. Gleixner KV, Ferenc V, Peter B, Gruze A, Meyer RA, Hadzijusufovic E, et al. Pololike kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Cancer Research 2010; 70: 1513-23.
16. Nihal M, Stutz N, Schmit T, Ahmad N, Wood GS. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis. Cell Cycle 2011; 10: 1303-11.
17. Rath O, Kozielski F. Kinesins and cancer. Nature Reviews Cancer 2012; 12: 527-39.
18. WoodKW, Lad L, Luo L, Qian X, Knight SD, Nevins N, et al. Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 5839-44.
19. Theoclitou ME, Aquila B, Block MH, Brassil PJ, Castriotta L, Code E, et al. Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2] thiazolo[5,4-d]pyrimidin -6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent. Journal of Medicinal Chemistry 2011; 54: 6734-50.
20. Purcell JW, Davis J, Reddy M, Martin S, Samayoa K, Vo H, et al. Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer. Clinical Cancer Research 2010; 16: 566-76.
21. Woessner R, Tunquist B, Lemieux C, Chlipala E, Jackinsky S, Dewolf Jr W, et al. ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models. Anticancer Research 2009; 29: 4373-80.
22. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clinical Cancer Research 2008; 14: 5000-5.
23. Kumar B, Yadav A, Lang JC, Cipolla MJ, Schmitt AC, Arradaza N, et al. YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels. Molecular Cancer Therapeutics 2012; 11: 1988-98.
24. Hansen JB, Fisker N, Westergaard M, Kjaerulff LS, Hansen HF, Thrue CA, et al. SPC3042: a proapoptotic survivin inhibitor. Molecular Cancer Therapeutics 2008; 7: 2736-45.
25. De Antoni A, Maffini S, Knapp S, Musacchio A, Santaguida S. A small-molecule inhibitor of Haspin alters the kinetochore functions of Aurora B. The Journal of Cell Biology 2012; 199: 269-84.
26. Huertas D, SolerM, MoretoJ, VillanuevaA, MartinezA, VidalA, et al. Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin. Oncogene 2012; 31: 1408-18.
27. Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clinical Cancer Research 2011; 17: 2799-806.
28. Hashimoto O, Shinkawa M, Torimura T, Nakamura T, Selvendiran K, Sakamoto M, et al. Cell cycle regulation bythe Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. BMC Cancer 2006; 6: 292.
29. Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD, et al. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. Journal of Clinical Oncology 2010; 28: 3015-22.
30. Mahadevan D, Plummer R, Squires MS, RensvoldD, Kurtin S, Pretzinger C, et al. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Annals of Oncology 2011; 22: 2137-43.
31. Le Tourneau C, Faivre S, Laurence V, Delbaldo C, Vera K, Girre V, et al. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. European Journal of Cancer 2010; 46: 3243-50.
32. Karp JE, Blackford A, Smith BD, Alino K, Seung AH, Bolanos-Meade J, et al. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leukemia Research 2010; 34: 877-82.
33. Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012; 119: 4597-607.
34. Dickson MA, Tap WD, Keohan ML, D'Angelo SP, Gounder MM, Antonescu CR, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. Journal of Clinical Oncology 2013; 31: 2024-8.
35. Matulonis UA, SharmaS, Ghamande S, Gordon MS, Del Prete SA, Ray-Coquard I, et al. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecologic Oncology 2012; 127: 63-9.
36. Dees EC, Cohen RB, von Mehren M, Stinchcombe TE, Liu H, Venkatakrishnan K, et al. Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clinical Cancer Research 2012; 18: 4775-84.
37. Cervantes A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K, et al. Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. Clinical Cancer Research 2012; 18: 4764-74.
38. Lowenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N, et al. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood 2011; 118: 6030-6.
39. Boss DS, Witteveen PO, van der SarJ, Lolkema MP, Voest EE, Stockman PK, et al. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Annals of Oncology 2011; 22: 431-7.
40. Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA, et al. MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Leukemia 2013; 27: 113-7.
41. Traynor AM, Hewitt M, Liu G, Flaherty KT, Clark J, Freedman SJ, et al. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 2011; 67: 305-14.
42. Diamond JR, Eckhardt SG, Tan AC, Newton TP, Selby HM, Brunkow KL, et al. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. Clinical Cancer Research 2013; 19: 291-303.
43. Meulenbeld HJ, Bleuse JP, Vinci EM, Raymond E, Vitali G, Santoro A, et al. Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU International 2013; 111: 44-52.
44. Arkenau HT, Plummer R, Molife LR, Olmos D, Yap TA, Squires M, et al. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Annals of Oncology 2012; 23: 1307-13.
45. Schoffski P, Jones SF, Dumez H, Infante JR, Van Mieghem E, Fowst C, et al. Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmaco-dynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. European Journal of Cancer 2011; 47: 2256-64.
46. MaWW, MessersmithWA, Dy GK, Weekes CD, WhitworthA, RenC, et al. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. Clinical Cancer Research 2012; 18: 2048-55.
47. Schoffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P, et al. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. European Journal of Cancer 2012; 48: 179-86.
48. Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, et al. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clinical Cancer Research 2011; 17: 3420-30.
49. Weiss L, Efferth T. Polo-like kinase 1 as target for cancer therapy. Experimental Hematology & Oncology 2012; 1: 38.
50. Souid AK, Dubowy RL, Ingle AM, Conlan MG, Sun J, Blaney SM, et al. A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer 2010; 55: 1323-8.
51. Burris HA, 3rd, Jones SF, Williams DD, Kathman SJ, Hodge JP, et al. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors. Investigational New Drugs 2011; 29: 467-72.
52. Khoury HJ, Garcia-Manero G, Borthakur G, Kadia T, Foudray MC, Arellano M, et al. A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer 2013; 118: 3556-64.
53. Jones R, Vuky J, Elliott T, Mead G, Arranz JA, Chester J, et al. Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Investigational New Drugs 2012; 31: 1001-7.
54. Holen KD, Belani CP, Wilding G, Ramalingam S, Volkman JL, Ramanathan RK, et al. A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish arecommended phase II dose. Cancer Chemotherapy and Pharmacology 2011; 67: 447-54.
55. Haupenthal J, Bihrer V, Korkusuz H, Kollmar O, Schmithals C, Kriener S, et al. Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels. Neoplasia 2012; 14: 410-9.
56. Mitchison TJ. The proliferation rate paradox in antimitotic chemotherapy. Molecular Biology of the Cell 2012; 23: 1-6.
57. Brito DA, Rieder CL. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Current Biology 2006; 16: 1194-200. (Pubitemid 43867292)
58. Galan-Malo P, Vela L, Gonzalo O, Calvo-Sanjuan R, Gracia-Fleta L, Naval J, et al. Cell fate after mitotic arrest in different tumor cells is determined by the balance between slippage and apoptotic threshold. Toxicology and Applied Pharmacology 2012; 258: 384-93.
59. Morais da Silva S, Moutinho-Santos T, Sunkel CE. A tumor suppressor role of the Bub3 spindle checkpoint protein after apoptosis inhibition. Journal of Cell Biology 2013; 201: 385-93.
60. Sakurikar N, Eichhorn JM, Chambers TC. Cyclin-dependent kinase-1 (Cdk1)/ cyclin B1 dictates cell fate after mitotic arrest via phosphoregulation of antiapoptotic Bcl-2 proteins. Journal of Biological Chemistry 2012; 287: 39193-204.
61. Harley ME, Allan LA, Sanderson HS, Clarke PR. Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO Journal 2010; 29: 2407-20.
62. Chu R, Terrano DT, Chambers TC. Cdk1/cyclin B plays a key role in mitotic arrest-induced apoptosis by phosphorylation of Mcl-1, promoting its degradation and freeing Bak from sequestration. Biochemical Pharmacology 2012; 83: 199-206.
63. Jang MS, Lee SJ, Kang NS, Kim E. Cooperative phosphorylation of FADD by AurA and Plk1 in response to taxol triggers both apoptotic and necrotic cell death. Cancer Research 2011; 71: 7207-15.
64. Zou Z, YuanZ, Zhang Q, LongZ, Chen J, Tang Z, et al. Aurora kinase Ainhibition-induced autophagy triggers drug resistance in breast cancer cells. Autophagy 2012; 8: 1798-810.
65. Karp JE, Smith BD, Resar LS, Greer JM, Blackford A, Zhao M, et al. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood 2011; 117: 3302-10.
66. Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z, et al. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biology and Therapy 2011; 12: 598-609.
67. Mitchell JB, Choudhuri R, Fabre K, Sowers AL, Citrin D, Zabludoff SD, et al. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clinical Cancer Research 2010; 16: 2076-84.
68. Zhang C, Yan Z, Painter CL, Zhang Q, Chen E, Arango ME, et al. PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts. Clinical Cancer Research 2009; 15: 4630-4640.
69. Matthews DJ, Yakes FM, Chen J, Tadano M, Bornheim L, Clary DO, et al. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 2007; 6: 104-10. (Pubitemid 46173886)
70. Siemeister G, Lucking U, Wengner AM, Lienau P, Steinke W, Schatz C, et al. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application. Molecular Cancer Therapeutics 2012; 11: 2265-73.
71. Payton M, Bush TL, Chung G, Ziegler B, Eden P, McElroy P, et al. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Research 2010; 70: 9846-54.
72. Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, et al. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 2011; 67: 945-54.
73. Shiotsu Y, Kiyoi H, Ishikawa Y, Tanizaki R, Shimizu M, Umehara H, et al. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood 2009; 114: 1607-17.
74. Shimomura T, Hasako S, Nakatsuru Y, Mita T, Ichikawa K, Kodera T, et al. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Molecular Cancer Therapeutics 2010; 9: 157-66.
75. Hardwicke MA, Oleykowski CA, Plant R, Wang J, Liao Q, Moss K, et al. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Molecular Cancer Therapeutics 2009; 8: 1808-17.
76. Arbitrario JP, Belmont BJ, Evanchik MJ, Flanagan WM, Fucini RV, Hansen SK, et al. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemotherapy and Pharmacology 2010; 65: 707-17.
77. Hikichi Y, Honda K, Hikami K, Miyashita H, Kaieda I, Murai S, et al. TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Molecular Cancer Therapeutics 2012; 11: 700-9.
78. Holen K, DiPaola R, Liu G, Tan AR, Wilding G, Hsu K, et al. A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors. Investigational New Drugs 2013; 30: 1088-95.
79. Chung V, Heath EI, Schelman WR, Johnson BM, Kirby LC, Lynch KM, et al. First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer. Cancer Chemotherapy and Pharmacology 2012; 69: 733-41.
80. Liu X, Shi S, Lam F, Pepper C, Fischer PM, Wang S. C.D.K.I-71 a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol. International Journal of Cancer 2012; 130: 1216-26.
81. Cho SJ, Kim YJ, Surh YJ, Kim BM, Lee SK. Ibulocydine is a novel prodrug Cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells. Journal of Biological Chemistry 2011; 286: 19662-71.
82. Hikita T, Oneyama C, Okada M, Purvalanol A. a CDK inhibitor, effectively suppresses Src-mediated transformation by inhibiting both CDKs and c-Src. Genes to Cells 2010; 15: 1051-62.
83. Li M, Jung A, Ganswindt U, Marini P, Friedl A, Daniel PT, et al. Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways. Biochemical Pharmacology 2010; 79: 122-9.
84. Yuan J, Sanhaji M, Kramer A, Reindl W, Hofmann M, Kreis NN, et al. Polo-box domain in hibitor poloxin activates the spindle assembly check point and in hibits tumor growth in vivo. American Journal of Pathology 2011; 179: 2091-9.
85. Wiltshire C, Singh BL, Stockley J, Fleming J, Doyle B, Barnetson R, et al. Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition. Molecular Cancer Therapeutics 2010; 9: 1730-9.
86. Chen Y, Chow JP, Poon RY. Inhibition of Eg5 acts synergistically with checkpoint abrogation in promoting mitotic catastrophe. Molecular Cancer Research 2012; 10: 626-35.
87. Chen J, Pise-Masison CA, Shih JH, Morris JC, Janik JE, Conlon KC, et al. Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia. Blood 2013; 121: 2029-37.
88. Colombo R, Caldarelli M, Mennecozzi M, Giorgini ML, Sola F, Cappella P, et al. Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Research 2010; 70: 10255-64.
89. Tardif KD, Rogers A, Cassiano J, Roth BL, Cimbora DM, McKinnon R, et al. Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1. Molecular Cancer Therapeutics 2011; 10: 2267-75.